<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Cover" roleURI="http://tonixpharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://tonixpharma.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://tonixpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CondensedConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Business" roleURI="http://tonixpharma.com/role/Business" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SignificantAccountingPolicies" roleURI="http://tonixpharma.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Inventory" roleURI="http://tonixpharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#PropertyAndEquipmentNet" roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#IntangibleAssets" roleURI="http://tonixpharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#FairValueMeasurements" roleURI="http://tonixpharma.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#OtherBalanceSheetInformation" roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformation" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#DebtFinancing" roleURI="http://tonixpharma.com/role/DebtFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#StockholdersEquity" roleURI="http://tonixpharma.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Revenues" roleURI="http://tonixpharma.com/role/Revenues" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#AssetPurchaseAgreementWithUpsher-smith" roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smith" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SaleAndPurchaseOfCommonStock" roleURI="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Stock-basedCompensation" roleURI="http://tonixpharma.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#WarrantsToPurchaseCommonStock" roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Leases" roleURI="http://tonixpharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Commitments" roleURI="http://tonixpharma.com/role/Commitments" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SubsequentEvents" roleURI="http://tonixpharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SignificantAccountingPoliciesTables" roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#InventoryTables" roleURI="http://tonixpharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#PropertyAndEquipmentNetTables" roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#IntangibleAssetsTables" roleURI="http://tonixpharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#OtherBalanceSheetInformationTables" roleURI="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#RevenuesTables" roleURI="http://tonixpharma.com/role/RevenuesTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SaleAndPurchaseOfCommonStockTables" roleURI="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Stock-basedCompensationTables" roleURI="http://tonixpharma.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#WarrantsToPurchaseCommonStockTables" roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#LeasesTables" roleURI="http://tonixpharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#BusinessDetailsNarrative" roleURI="http://tonixpharma.com/role/BusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#InformationAboutSignificantSegmentExpensesRegularlyProvidedToCodmIsAsFollowsInThousandsDetails" roleURI="http://tonixpharma.com/role/InformationAboutSignificantSegmentExpensesRegularlyProvidedToCodmIsAsFollowsInThousandsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinCondensedConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInCondensedConsolidatedStatementOfCashFlowsDetails" roleURI="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinCondensedConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInCondensedConsolidatedStatementOfCashFlowsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfMarch312026And2025AreAsFollowsDetails" roleURI="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfMarch312026And2025AreAsFollowsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#ComponentsOfInventoryConsistedOfFollowingInThousandsDetails" roleURI="http://tonixpharma.com/role/ComponentsOfInventoryConsistedOfFollowingInThousandsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" roleURI="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#FollowingTableProvidesGrossCarryingAmountAndAccumulatedAmortizationForEachMajorClassOfIntangibleAssetDetails" roleURI="http://tonixpharma.com/role/FollowingTableProvidesGrossCarryingAmountAndAccumulatedAmortizationForEachMajorClassOfIntangibleAssetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" roleURI="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#DebtFinancingDetailsNarrative" roleURI="http://tonixpharma.com/role/DebtFinancingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#StockholdersEquityDetailsNarrative" roleURI="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CompanysNetProductRevenuesAreSummarizedBelowDetails" roleURI="http://tonixpharma.com/role/CompanysNetProductRevenuesAreSummarizedBelowDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#RevenuesDetailsNarrative" roleURI="http://tonixpharma.com/role/RevenuesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#AssetPurchaseAgreementWithUpsher-smithDetailsNarrative" roleURI="http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smithDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SaleAndPurchaseOfCommonStockDetailsNarrative" roleURI="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CompanyRepurchasedFollowingCapitalStockDetails" roleURI="http://tonixpharma.com/role/CompanyRepurchasedFollowingCapitalStockDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SummaryOfStockOptionActivityAndRelatedInformationForPlansForThreeMonthsEndedMarch312026IsAsFollowsDetails" roleURI="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForThreeMonthsEndedMarch312026IsAsFollowsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#AssumptionsUsedInValuationOfStockOptionsGrantedDuringThreeMonthsEndedMarch312026And2025WereAsFollowsDetails" roleURI="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringThreeMonthsEndedMarch312026And2025WereAsFollowsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtMarch312026Details" roleURI="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtMarch312026Details" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#WarrantsToPurchaseCommonStockDetailsNarrative" roleURI="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#AtMarch312026FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" roleURI="http://tonixpharma.com/role/AtMarch312026FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#OtherInformationRelatedToLeasesIsAsFollowsDetails" roleURI="http://tonixpharma.com/role/OtherInformationRelatedToLeasesIsAsFollowsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#LeasesDetailsNarrative" roleURI="http://tonixpharma.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#CommitmentsDetailsNarrative" roleURI="http://tonixpharma.com/role/CommitmentsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="tnxp-20260331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FIFOInventoryAmount" xlink:label="loc_us-gaapFIFOInventoryAmount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapFIFOInventoryAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="loc_us-gaapGovernmentAssistanceNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapGovernmentAssistanceNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:title="00000009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Business" xlink:title="999015 - Disclosure - BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPolicies" xlink:title="999016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Inventory" xlink:title="999017 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNet" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IntangibleAssets" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurements" xlink:title="999020 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformation" xlink:title="999021 - Disclosure - OTHER BALANCE SHEET INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/DebtFinancing" xlink:title="999022 - Disclosure - DEBT FINANCING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquity" xlink:title="999023 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Revenues" xlink:title="999024 - Disclosure - REVENUES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smith" xlink:title="999025 - Disclosure - ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStock" xlink:title="999026 - Disclosure - SALE AND PURCHASE OF COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensation" xlink:title="999027 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStock" xlink:title="999028 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Leases" xlink:title="999029 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Commitments" xlink:title="999030 - Disclosure - COMMITMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEvents" xlink:title="999031 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="999033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/InventoryTables" xlink:title="999034 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="999035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/IntangibleAssetsTables" xlink:title="999036 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherBalanceSheetInformationTables" xlink:title="999037 - Disclosure - OTHER BALANCE SHEET INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/RevenuesTables" xlink:title="999038 - Disclosure - REVENUES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockTables" xlink:title="999039 - Disclosure - SALE AND PURCHASE OF COMMON STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationTables" xlink:title="999040 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockTables" xlink:title="999041 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesTables" xlink:title="999042 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/BusinessDetailsNarrative" xlink:title="999043 - Disclosure - BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999044 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/InformationAboutSignificantSegmentExpensesRegularlyProvidedToCodmIsAsFollowsInThousandsDetails" xlink:title="999045 - Disclosure - Information about significant segment expenses regularly provided to the CODM is as follows (in thousands): (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableProvidesReconciliationOfCashCashEquivalentsAndRestrictedCashReportedWithinCondensedConsolidatedBalanceSheetsThatSumToTotalOfSameAmountsShownInCondensedConsolidatedStatementOfCashFlowsDetails" xlink:title="999046 - Disclosure - The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PotentiallyDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerShareAsOfMarch312026And2025AreAsFollowsDetails" xlink:title="999047 - Disclosure - Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of March 31, 2026, and 2025, are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfInventoryConsistedOfFollowingInThousandsDetails" xlink:title="999048 - Disclosure - The components of inventory consisted of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="tnxp-20260331.xsd#tnxp_InventoryCurrentAndNoncurrent" xlink:label="loc_tnxpInventoryCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tnxpInventoryCurrentAndNoncurrent" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaapInventoryWorkInProcessNetOfReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tnxpInventoryCurrentAndNoncurrent" xlink:to="loc_us-gaapInventoryWorkInProcessNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_tnxpInventoryCurrentAndNoncurrent" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/PropertyAndEquipmentNetConsistedOfFollowingInThousandsDetails" xlink:title="999049 - Disclosure - Property and equipment, net consisted of the following (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableProvidesGrossCarryingAmountAndAccumulatedAmortizationForEachMajorClassOfIntangibleAssetDetails" xlink:title="999050 - Disclosure - The following table provides the gross carrying amount and accumulated amortization for each major class of intangible asset: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/ComponentsOfSelectedCaptionsInConsolidatedBalanceSheetsConsistOfDetails" xlink:title="999052 - Disclosure - Components of selected captions in the consolidated balance sheets consist of: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaapContractWithCustomerAssetNetCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapContractWithCustomerAssetNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Supplies" xlink:label="loc_us-gaapSupplies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapSupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20260331.xsd#tnxp_PrepaidPrescriptionDrugUserFeeActFees" xlink:label="loc_tnxpPrepaidPrescriptionDrugUserFeeActFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_tnxpPrepaidPrescriptionDrugUserFeeActFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20260331.xsd#tnxp_CompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:label="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpCompensationAndCompensationRelatedAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaapCustomerRefundLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapCustomerRefundLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="tnxp-20260331.xsd#tnxp_ProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_tnxpProfessionalFeesAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/DebtFinancingDetailsNarrative" xlink:title="999053 - Disclosure - DEBT FINANCING (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999054 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CompanysNetProductRevenuesAreSummarizedBelowDetails" xlink:title="999055 - Disclosure - The Company&#8217;s net product revenues are summarized below: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/RevenuesDetailsNarrative" xlink:title="999056 - Disclosure - REVENUES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssetPurchaseAgreementWithUpsher-smithDetailsNarrative" xlink:title="999057 - Disclosure - ASSET PURCHASE AGREEMENT WITH UPSHER-SMITH (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SaleAndPurchaseOfCommonStockDetailsNarrative" xlink:title="999058 - Disclosure - SALE AND PURCHASE OF COMMON STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CompanyRepurchasedFollowingCapitalStockDetails" xlink:title="999059 - Disclosure - The Company repurchased the following capital stock: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SummaryOfStockOptionActivityAndRelatedInformationForPlansForThreeMonthsEndedMarch312026IsAsFollowsDetails" xlink:title="999060 - Disclosure - A summary of the stock option activity and related information for the Plans for the three months ended March 31, 2026, is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AssumptionsUsedInValuationOfStockOptionsGrantedDuringThreeMonthsEndedMarch312026And2025WereAsFollowsDetails" xlink:title="999061 - Disclosure - The assumptions used in the valuation of stock options granted during the three months ended March 31, 2026, and 2025 were as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999062 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/FollowingTableSummarizesInformationWithRespectToOutstandingWarrantsToPurchaseCommonStockOfCompanyAtMarch312026Details" xlink:title="999063 - Disclosure - The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2026: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/WarrantsToPurchaseCommonStockDetailsNarrative" xlink:title="999064 - Disclosure - WARRANTS TO PURCHASE COMMON STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/AtMarch312026FutureMinimumLeasePaymentsForOperatingLeasesWithNon-cancelableTermsOfMoreThanOneYearWereAsFollowsInThousandsDetails" xlink:title="999065 - Disclosure - At March 31, 2026, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/OtherInformationRelatedToLeasesIsAsFollowsDetails" xlink:title="999066 - Disclosure - Other information related to leases is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/LeasesDetailsNarrative" xlink:title="999067 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/CommitmentsDetailsNarrative" xlink:title="999068 - Disclosure - COMMITMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://tonixpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999069 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
